The final decision and publication of guidance for ocrelizumab was due on 31 October, and it is thought that it would have been rejected on the grounds of cost effectiveness. However, the MS Trust has now learned that the final decision has been postponed, while further discussions take place between the Drug Company and NHS England.
There are currently no approved treatments of PPMS. However, NICE has acknowledged that the condition can have a substantial impact on a person’s life, as well as affecting their families.
Clinical trials have shown that ocrelizumab can slow the progression of disability in early active PPMS, which could enable PPMSers to maintain their independence and carry on in the world of work for longer.
The MS community will now await a final decision, but no official date has yet been published.
Source: MS-UK 08/11/2018